We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

By LabMedica International staff writers
Posted on 06 Mar 2025
Print article
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where it originates. However, in some instances, DCIS progresses into invasive breast cancer, which can become life-threatening. Despite years of research, determining which cases require aggressive treatment and which can be safely monitored has remained difficult. Clinical decisions about treatment usually depend on the size and grade of the DCIS lesion, but these factors do not always reliably predict the behavior of the cancer. Identifying a better way to predict which cases are likely to become more aggressive could significantly enhance treatment strategies. Now, researchers have discovered a potential method for predicting the likelihood of cancer spreading by assessing the "stickiness" of tumor cells. This breakthrough, made possible by a specially designed microfluidic device, could help doctors identify high-risk patients and tailor their treatment plans more effectively.

The innovative device, developed by scientists at the University of California San Diego (La Jolla, CA, USA), works by pushing tumor cells through fluid-filled chambers and sorting them based on how well they adhere to the walls of the chambers. In tests with tumor cells collected from patients with various stages of breast cancer, the researchers identified a distinct pattern: cells from patients with more aggressive cancers were less sticky (weakly adherent), while cells from patients with less aggressive cancers were more sticky (strongly adherent). The team’s previous research had already shown that cancer cells with weak adhesion are more likely to migrate and invade surrounding tissues, compared to cells with stronger adhesion. By testing this concept on patient tumor samples, the team advanced their work, demonstrating that the adhesion strength of tumor cells varies and that this characteristic might help predict whether a patient’s cancer will spread.

The device, about the size of an index card, consists of microfluidic chambers that are coated with adhesive proteins found in breast tissue, like fibronectin. When tumor cells are introduced into the chambers, they adhere to the fibronectin coating. The cells are then subjected to increasing shear stress as fluid flows through the chambers. By observing where cells detach under specific stress levels, the researchers categorize them as weakly or strongly adherent. In their most recent study, the team used this device to examine cell adhesion in DCIS samples. The device was tested in an investigator-initiated trial with samples from 16 patients, including normal breast tissue, DCIS tumors, and aggressive breast cancer tumors from patients with invasive ductal and lobular carcinomas. The results, published in Cell Reports, revealed that aggressive breast cancer samples contained weakly adherent cells, while normal breast tissue samples contained strongly adherent cells. DCIS samples showed intermediate levels of adhesion, but there was significant variability across patients. Moving forward, the team plans to monitor DCIS patients over the next five years to assess whether adhesion strength correlates with metastatic progression. If their hypothesis proves correct, this device could provide oncologists with a powerful tool to inform treatment decisions, potentially recommending more aggressive treatments for patients with tumors showing weak cell adhesion.

“Right now, we don’t have a reliable way to identify which DCIS patients are at risk of developing more aggressive breast cancer. Our device could change that,” said study senior author Adam Engler, a professor in the Shu Chien-Gene Lay Department of Bioengineering at the UC San Diego Jacobs School of Engineering. “Our hope is that this device will allow us to prospectively identify those at highest risk, so that we can intervene before metastasis occurs.”

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.